,Lilley’s Pharmacology NCLEX Review: 58 Chapters of Targeted
Test Questions
Complete 58-Chapter Coverage | 1,160 NCLEX-Style Questions
| Verified and Explained
Aligns with Pharmacology and the Nursing Process, 10th
Edition
"Master Every Chapter – Pass with Confidence | Rationales
Backed by Evidence-Based Guidelines"
Contents:
PART 1: PHARMACOLOGY BASICS
1. The Nursing Process and Drug Therapy
Introduces assessment, diagnosis, planning, implementation, and evaluation in
pharmacologic care—emphasizing patient safety, evidence-based practice, and
documentation.
2. Pharmacologic Principles
Covers drug absorption, distribution, metabolism, and excretion (ADME); mechanisms
of action; dose-response relationships; and therapeutic vs. toxic effects.
3. Lifespan Considerations
Examines how age-related physiological changes in pediatric and geriatric populations
influence pharmacokinetics and dosing.
4. Cultural, Legal, and Ethical Considerations
Highlights cultural competence, informed consent, legal responsibilities, patient rights,
and ethical dilemmas in drug therapy.
5. Medication Errors: Preventing and Responding
Defines error types, contributing factors, reporting systems, and strategies like the “five
rights” and root-cause analysis to improve safety.
6. Patient Education and Drug Therapy
Focuses on teaching strategies to enhance adherence, literacy, and informed decision-
making, using clear communication and written materials.
, 7. Over-the-Counter Drugs and Herbal and Dietary Supplements
Reviews common OTC medications, herbal remedies, regulation issues, safety profiles,
and drug–supplement interactions.
8. Gene Therapy and Pharmacogenomics
Explains how genetic factors affect drug response and the future impact of gene therapy
and personalized medicine.
9. Photo Atlas of Drug Administration
Visual guide to administering medications by various routes—oral, topical, injectable,
inhalational, and parenteral—with proper technique.
PART 2: DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM
10. Analgesic Drugs
Discusses opioid and nonopioid pain relievers, multimodal approaches, and safety
considerations for acute and chronic pain.
11. General and Local Anesthetics
Explains mechanisms, administration routes, perioperative monitoring, and
complications of anesthetic agents.
12. Central Nervous System Depressants and Muscle Relaxants
Covers sedatives, hypnotics, benzodiazepines, barbiturates, and their use in anxiety,
insomnia, and muscle spasms.
13. Central Nervous System Stimulants and Related Drugs
Focus on ADHD therapies, narcolepsy drugs, and decongestants, detailing stimulant
action and abuse potential.
14. Antiepileptic Drugs
Presents seizure types, drug classifications, mechanisms, monitoring, and dosing for
epilepsy management.
15. Antiparkinson Drugs
Reviews dopaminergic agents, anticholinergics, and COMT inhibitors to alleviate
Parkinson’s symptoms.
16. Psychotherapeutic Drugs
Details antidepressants, antipsychotics, mood stabilizers, side effects, and drug selection
strategies for mental health disorders.
, 17. Substance Use Disorder
Covers addiction biology, detox agents, maintenance therapies (e.g., methadone,
buprenorphine), and relapse prevention.
PART 3: DRUGS AFFECTING THE AUTONOMIC NERVOUS SYSTEM
18. Adrenergic Drugs
Explains sympathetic agonists for shock, asthma, and cardiac support, including dosing
and side effect profiles.
19. Adrenergic-Blocking Drugs
Details beta- and alpha-blockers used in hypertension, angina, and arrhythmias, along
with contraindications.
20. Cholinergic Drugs
Covers parasympathomimetics used for glaucoma, myasthenia gravis, and postoperative
ileus.
21. Cholinergic-Blocking Drugs
Describes anticholinergics for motion sickness, urinary incontinence, and respiratory
conditions.
PART 4: DRUGS AFFECTING THE CARDIOVASCULAR AND RENAL SYSTEMS
22. Antihypertensive Drugs
Reviews ACE inhibitors, ARBs, diuretics, calcium-channel blockers, and lifestyle factors in
blood pressure control.
23. Antianginal Drugs
Includes nitrates, beta-blockers, and calcium-channel blockers to relieve chest pain and
optimize cardiac oxygenation.
24. Heart Failure Drugs
Focuses on ACE inhibitors, beta-blockers, diuretics, and inotropes for managing chronic
and acute heart failure.
25. Antidysrhythmic Drugs
Classifies antiarrhythmics by Vaughan-Williams and addresses indication, toxicity, and
monitoring.
26. Coagulation Modifier Drugs
Covers anticoagulants, antiplatelets, and fibrinolytics in thrombosis, stroke prevention,
and device-related clot prevention.
, 27. Antilipemic Drugs
Discusses statins, fibric acids, and PCSK9 inhibitors for cholesterol management.
28. Diuretic Drugs
Explains classifications, indications, electrolyte effects, and use in hypertension and fluid
overload.
29. Fluids and Electrolytes
Reviews IV fluid types and fluid/electrolyte balance in acute and chronic conditions.
PART 5: DRUGS AFFECTING THE ENDOCRINE AND REPRODUCTIVE SYSTEMS
30. Pituitary Drugs
Discusses hormones and analogs for endocrine disorders, diagnostic tests, and diabetes
insipidus.
31. Thyroid and Antithyroid Drugs
Focuses on replacement therapy and antithyroid drugs, dosing, and monitoring.
32. Antidiabetic Drugs
Covers insulins, oral hypoglycemics, and newer agents used in diabetes care.
33. Adrenal Drugs
Reviews corticosteroids and mineralocorticoids, their uses, side effects, and tapering
strategies.
34. Women’s Health Drugs
Includes contraceptives, hormone therapy, and reproductive health medications.
35. Men’s Health Drugs
Covers medications for androgen deficiency, erectile dysfunction, and fertility
treatments.
PART 6: DRUGS AFFECTING THE RESPIRATORY SYSTEM
36. Antihistamines, Decongestants, Antitussives, and Expectorants
Details symptomatic relief agents for colds, allergies, and airway secretions.
37. Respiratory Drugs
Reviews bronchodilators, corticosteroids, leukotriene modifiers, and biologics used in
asthma and COPD.
,PART 7: ANTIINFECTIVE AND ANTIINFLAMMATORY DRUGS
38. Antibiotics Part 1
Covers cell wall and protein synthesis inhibitors (e.g., beta-lactams, macrolides), their
action and resistance.
39. Antibiotics Part 2
Focuses on other classes (e.g., quinolones, aminoglycosides), spectrum, dosing, and
toxicity.
40. Antiviral Drugs
Discusses agents for influenza, HIV, herpes, hepatitis, CMV, and emerging infections.
41. Antitubercular Drugs
Details first- and second-line TB medications, regimens, duration, and monitoring.
42. Antifungal Drugs
Reviews polyenes, azoles, and echinocandins—uses and resistance patterns.
43. Antimalarial, Antiprotozoal, and Anthelmintic Drugs
Covers medications used for malaria, giardiasis, and parasitic infections.
44. Antiinflammatory and Antigout Drugs
Includes NSAIDs, corticosteroids, and urate-lowering agents used for inflammation and
gout.
PART 8: CHEMOTHERAPEUTIC DRUGS AND BIOLOGIC AND IMMUNE MODIFIERS
45. Antineoplastic Drugs Part 1: Cancer Overview and Cell Cycle–Specific Drugs
Introduces chemotherapy principles and cell cycle-specific agents (e.g., vinca alkaloids,
antimetabolites).
46. Antineoplastic Drugs Part 2: Cell Cycle–Nonspecific Drugs and Miscellaneous Drugs
Discusses nonspecific agents (e.g., alkylating agents), targeted therapies, and supportive
care.
47. Biologic Response–Modifying and Antirheumatic Drugs
Examines biologics (e.g., TNF inhibitors, DMARDs) used in cancer and autoimmune
disorders.
48. Immunosuppressant Drugs
Covers drugs used in transplant medicine to prevent rejection.
, 49. Immunizing Drugs
Reviews vaccines, passive and active immunity, schedules, and public health
implications.
PART 9: DRUGS AFFECTING THE GASTROINTESTINAL SYSTEM AND NUTRITION
50. Acid-Controlling Drugs
Reviews antacids, H₂ blockers, proton-pump inhibitors, and mucosal protectants.
51. Bowel Disorder Drugs
Covers laxatives, antidiarrheals, and IBS-specific medications.
52. Antiemetic and Antinausea Drugs
Discusses serotonin antagonists, dopamine antagonists, and other antiemetics.
53. Vitamins and Minerals
Reviews essential micronutrients—their roles, deficiencies, dosing, and toxicity risks.
54. Anemia Drugs
Covers iron, erythropoiesis-stimulating agents, and vitamin B₁₂/folate therapies.
55. Nutritional Supplements
Reviews enteral/parenteral nutrition, amino acids, and essential nutritional support.
PART 10: DERMATOLOGIC, OPHTHALMIC, AND OTIC DRUGS
56. Dermatologic Drugs
Covers topical/systemic meds for acne, psoriasis, dermatitis, and derm infections.
57. Ophthalmic Drugs
Reviews medications for glaucoma, infections, and inflammations of the eye.
58. Otic Drugs
Discusses ear medications used to treat infections, inflammation, and cerumen
impaction.
,1. Which route of drug administration generally has the
slowest onset of action?
A. Intravenous
B. Intramuscular
C. Subcutaneous
D. Oral (Correct)
Rationale: Oral drugs must pass through the GI tract and
undergo first-pass metabolism, delaying absorption and
onset compared to parenteral routes.
2. A nurse teaches that which factor most influences a
drug’s absorption?
A. Chemical stability of the drug
B. Blood flow to the absorption site (Correct)
C. Patient’s age
D. Drug’s half-life
Rationale: Adequate perfusion at the site (e.g., muscle vs.
fat) is critical for rapid uptake into the circulation.
3. Which pH condition in the stomach promotes absorption
of weak-acid drugs?
A. Alkaline (pH > 7)
B. Neutral (pH ≈ 7)
C. Acidic (pH < 3) (Correct)
D. Variable pH has no effect
Rationale: Weak acids remain nonionized in acidic
, environments, enhancing lipid solubility and membrane
crossing.
4. A patient with hypoalbuminemia is at increased risk for
toxicity because:
A. More drug is metabolized
B. More free (active) drug is available (Correct)
C. They excrete drug faster
D. Distribution volume decreases
Rationale: Low albumin means less protein binding;
unbound drug exerts pharmacologic and toxic effects.
5. Which body compartment typically contains the largest
volume of distribution for lipophilic drugs?
A. Plasma
B. Interstitial fluid
C. Adipose tissue (Correct)
D. Intracellular water
Rationale: Lipid-soluble agents accumulate in fat stores,
expanding apparent volume of distribution.
6. In aging adults, decreased lean body mass affects drug
distribution by:
A. Increasing hydrophilic drug volume
B. Decreasing fat-soluble drug volume
C. Reducing distribution of water-soluble drugs (Correct)
D. Enhancing protein binding
Rationale: Elderly have less total body water,
concentrating hydrophilic drugs in plasma.
, 7. The primary site of drug metabolism is the:
A. Kidney
B. Liver (Correct)
C. Spleen
D. Lungs
Rationale: Hepatic cytochrome P450 enzymes chemically
modify drugs to more water-soluble metabolites.
8. A “first-pass effect” refers to:
A. Initial receptor binding
B. Hepatic metabolism before systemic circulation
(Correct)
C. Distribution into tissues
D. Renal excretion
Rationale: Drugs absorbed from the GI tract go through
the portal vein and liver, where significant metabolism
may occur.
9. Which patient factor would most likely decrease hepatic
drug metabolism?
A. Nutritional status
B. Liver cirrhosis (Correct)
C. Polypharmacy
D. High albumin
Rationale: Cirrhosis impairs enzyme function and hepatic
blood flow, reducing clearance.
10. Renal excretion of a drug is increased by:
A. Decreasing urine pH for weak bases (Correct)
Test Questions
Complete 58-Chapter Coverage | 1,160 NCLEX-Style Questions
| Verified and Explained
Aligns with Pharmacology and the Nursing Process, 10th
Edition
"Master Every Chapter – Pass with Confidence | Rationales
Backed by Evidence-Based Guidelines"
Contents:
PART 1: PHARMACOLOGY BASICS
1. The Nursing Process and Drug Therapy
Introduces assessment, diagnosis, planning, implementation, and evaluation in
pharmacologic care—emphasizing patient safety, evidence-based practice, and
documentation.
2. Pharmacologic Principles
Covers drug absorption, distribution, metabolism, and excretion (ADME); mechanisms
of action; dose-response relationships; and therapeutic vs. toxic effects.
3. Lifespan Considerations
Examines how age-related physiological changes in pediatric and geriatric populations
influence pharmacokinetics and dosing.
4. Cultural, Legal, and Ethical Considerations
Highlights cultural competence, informed consent, legal responsibilities, patient rights,
and ethical dilemmas in drug therapy.
5. Medication Errors: Preventing and Responding
Defines error types, contributing factors, reporting systems, and strategies like the “five
rights” and root-cause analysis to improve safety.
6. Patient Education and Drug Therapy
Focuses on teaching strategies to enhance adherence, literacy, and informed decision-
making, using clear communication and written materials.
, 7. Over-the-Counter Drugs and Herbal and Dietary Supplements
Reviews common OTC medications, herbal remedies, regulation issues, safety profiles,
and drug–supplement interactions.
8. Gene Therapy and Pharmacogenomics
Explains how genetic factors affect drug response and the future impact of gene therapy
and personalized medicine.
9. Photo Atlas of Drug Administration
Visual guide to administering medications by various routes—oral, topical, injectable,
inhalational, and parenteral—with proper technique.
PART 2: DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM
10. Analgesic Drugs
Discusses opioid and nonopioid pain relievers, multimodal approaches, and safety
considerations for acute and chronic pain.
11. General and Local Anesthetics
Explains mechanisms, administration routes, perioperative monitoring, and
complications of anesthetic agents.
12. Central Nervous System Depressants and Muscle Relaxants
Covers sedatives, hypnotics, benzodiazepines, barbiturates, and their use in anxiety,
insomnia, and muscle spasms.
13. Central Nervous System Stimulants and Related Drugs
Focus on ADHD therapies, narcolepsy drugs, and decongestants, detailing stimulant
action and abuse potential.
14. Antiepileptic Drugs
Presents seizure types, drug classifications, mechanisms, monitoring, and dosing for
epilepsy management.
15. Antiparkinson Drugs
Reviews dopaminergic agents, anticholinergics, and COMT inhibitors to alleviate
Parkinson’s symptoms.
16. Psychotherapeutic Drugs
Details antidepressants, antipsychotics, mood stabilizers, side effects, and drug selection
strategies for mental health disorders.
, 17. Substance Use Disorder
Covers addiction biology, detox agents, maintenance therapies (e.g., methadone,
buprenorphine), and relapse prevention.
PART 3: DRUGS AFFECTING THE AUTONOMIC NERVOUS SYSTEM
18. Adrenergic Drugs
Explains sympathetic agonists for shock, asthma, and cardiac support, including dosing
and side effect profiles.
19. Adrenergic-Blocking Drugs
Details beta- and alpha-blockers used in hypertension, angina, and arrhythmias, along
with contraindications.
20. Cholinergic Drugs
Covers parasympathomimetics used for glaucoma, myasthenia gravis, and postoperative
ileus.
21. Cholinergic-Blocking Drugs
Describes anticholinergics for motion sickness, urinary incontinence, and respiratory
conditions.
PART 4: DRUGS AFFECTING THE CARDIOVASCULAR AND RENAL SYSTEMS
22. Antihypertensive Drugs
Reviews ACE inhibitors, ARBs, diuretics, calcium-channel blockers, and lifestyle factors in
blood pressure control.
23. Antianginal Drugs
Includes nitrates, beta-blockers, and calcium-channel blockers to relieve chest pain and
optimize cardiac oxygenation.
24. Heart Failure Drugs
Focuses on ACE inhibitors, beta-blockers, diuretics, and inotropes for managing chronic
and acute heart failure.
25. Antidysrhythmic Drugs
Classifies antiarrhythmics by Vaughan-Williams and addresses indication, toxicity, and
monitoring.
26. Coagulation Modifier Drugs
Covers anticoagulants, antiplatelets, and fibrinolytics in thrombosis, stroke prevention,
and device-related clot prevention.
, 27. Antilipemic Drugs
Discusses statins, fibric acids, and PCSK9 inhibitors for cholesterol management.
28. Diuretic Drugs
Explains classifications, indications, electrolyte effects, and use in hypertension and fluid
overload.
29. Fluids and Electrolytes
Reviews IV fluid types and fluid/electrolyte balance in acute and chronic conditions.
PART 5: DRUGS AFFECTING THE ENDOCRINE AND REPRODUCTIVE SYSTEMS
30. Pituitary Drugs
Discusses hormones and analogs for endocrine disorders, diagnostic tests, and diabetes
insipidus.
31. Thyroid and Antithyroid Drugs
Focuses on replacement therapy and antithyroid drugs, dosing, and monitoring.
32. Antidiabetic Drugs
Covers insulins, oral hypoglycemics, and newer agents used in diabetes care.
33. Adrenal Drugs
Reviews corticosteroids and mineralocorticoids, their uses, side effects, and tapering
strategies.
34. Women’s Health Drugs
Includes contraceptives, hormone therapy, and reproductive health medications.
35. Men’s Health Drugs
Covers medications for androgen deficiency, erectile dysfunction, and fertility
treatments.
PART 6: DRUGS AFFECTING THE RESPIRATORY SYSTEM
36. Antihistamines, Decongestants, Antitussives, and Expectorants
Details symptomatic relief agents for colds, allergies, and airway secretions.
37. Respiratory Drugs
Reviews bronchodilators, corticosteroids, leukotriene modifiers, and biologics used in
asthma and COPD.
,PART 7: ANTIINFECTIVE AND ANTIINFLAMMATORY DRUGS
38. Antibiotics Part 1
Covers cell wall and protein synthesis inhibitors (e.g., beta-lactams, macrolides), their
action and resistance.
39. Antibiotics Part 2
Focuses on other classes (e.g., quinolones, aminoglycosides), spectrum, dosing, and
toxicity.
40. Antiviral Drugs
Discusses agents for influenza, HIV, herpes, hepatitis, CMV, and emerging infections.
41. Antitubercular Drugs
Details first- and second-line TB medications, regimens, duration, and monitoring.
42. Antifungal Drugs
Reviews polyenes, azoles, and echinocandins—uses and resistance patterns.
43. Antimalarial, Antiprotozoal, and Anthelmintic Drugs
Covers medications used for malaria, giardiasis, and parasitic infections.
44. Antiinflammatory and Antigout Drugs
Includes NSAIDs, corticosteroids, and urate-lowering agents used for inflammation and
gout.
PART 8: CHEMOTHERAPEUTIC DRUGS AND BIOLOGIC AND IMMUNE MODIFIERS
45. Antineoplastic Drugs Part 1: Cancer Overview and Cell Cycle–Specific Drugs
Introduces chemotherapy principles and cell cycle-specific agents (e.g., vinca alkaloids,
antimetabolites).
46. Antineoplastic Drugs Part 2: Cell Cycle–Nonspecific Drugs and Miscellaneous Drugs
Discusses nonspecific agents (e.g., alkylating agents), targeted therapies, and supportive
care.
47. Biologic Response–Modifying and Antirheumatic Drugs
Examines biologics (e.g., TNF inhibitors, DMARDs) used in cancer and autoimmune
disorders.
48. Immunosuppressant Drugs
Covers drugs used in transplant medicine to prevent rejection.
, 49. Immunizing Drugs
Reviews vaccines, passive and active immunity, schedules, and public health
implications.
PART 9: DRUGS AFFECTING THE GASTROINTESTINAL SYSTEM AND NUTRITION
50. Acid-Controlling Drugs
Reviews antacids, H₂ blockers, proton-pump inhibitors, and mucosal protectants.
51. Bowel Disorder Drugs
Covers laxatives, antidiarrheals, and IBS-specific medications.
52. Antiemetic and Antinausea Drugs
Discusses serotonin antagonists, dopamine antagonists, and other antiemetics.
53. Vitamins and Minerals
Reviews essential micronutrients—their roles, deficiencies, dosing, and toxicity risks.
54. Anemia Drugs
Covers iron, erythropoiesis-stimulating agents, and vitamin B₁₂/folate therapies.
55. Nutritional Supplements
Reviews enteral/parenteral nutrition, amino acids, and essential nutritional support.
PART 10: DERMATOLOGIC, OPHTHALMIC, AND OTIC DRUGS
56. Dermatologic Drugs
Covers topical/systemic meds for acne, psoriasis, dermatitis, and derm infections.
57. Ophthalmic Drugs
Reviews medications for glaucoma, infections, and inflammations of the eye.
58. Otic Drugs
Discusses ear medications used to treat infections, inflammation, and cerumen
impaction.
,1. Which route of drug administration generally has the
slowest onset of action?
A. Intravenous
B. Intramuscular
C. Subcutaneous
D. Oral (Correct)
Rationale: Oral drugs must pass through the GI tract and
undergo first-pass metabolism, delaying absorption and
onset compared to parenteral routes.
2. A nurse teaches that which factor most influences a
drug’s absorption?
A. Chemical stability of the drug
B. Blood flow to the absorption site (Correct)
C. Patient’s age
D. Drug’s half-life
Rationale: Adequate perfusion at the site (e.g., muscle vs.
fat) is critical for rapid uptake into the circulation.
3. Which pH condition in the stomach promotes absorption
of weak-acid drugs?
A. Alkaline (pH > 7)
B. Neutral (pH ≈ 7)
C. Acidic (pH < 3) (Correct)
D. Variable pH has no effect
Rationale: Weak acids remain nonionized in acidic
, environments, enhancing lipid solubility and membrane
crossing.
4. A patient with hypoalbuminemia is at increased risk for
toxicity because:
A. More drug is metabolized
B. More free (active) drug is available (Correct)
C. They excrete drug faster
D. Distribution volume decreases
Rationale: Low albumin means less protein binding;
unbound drug exerts pharmacologic and toxic effects.
5. Which body compartment typically contains the largest
volume of distribution for lipophilic drugs?
A. Plasma
B. Interstitial fluid
C. Adipose tissue (Correct)
D. Intracellular water
Rationale: Lipid-soluble agents accumulate in fat stores,
expanding apparent volume of distribution.
6. In aging adults, decreased lean body mass affects drug
distribution by:
A. Increasing hydrophilic drug volume
B. Decreasing fat-soluble drug volume
C. Reducing distribution of water-soluble drugs (Correct)
D. Enhancing protein binding
Rationale: Elderly have less total body water,
concentrating hydrophilic drugs in plasma.
, 7. The primary site of drug metabolism is the:
A. Kidney
B. Liver (Correct)
C. Spleen
D. Lungs
Rationale: Hepatic cytochrome P450 enzymes chemically
modify drugs to more water-soluble metabolites.
8. A “first-pass effect” refers to:
A. Initial receptor binding
B. Hepatic metabolism before systemic circulation
(Correct)
C. Distribution into tissues
D. Renal excretion
Rationale: Drugs absorbed from the GI tract go through
the portal vein and liver, where significant metabolism
may occur.
9. Which patient factor would most likely decrease hepatic
drug metabolism?
A. Nutritional status
B. Liver cirrhosis (Correct)
C. Polypharmacy
D. High albumin
Rationale: Cirrhosis impairs enzyme function and hepatic
blood flow, reducing clearance.
10. Renal excretion of a drug is increased by:
A. Decreasing urine pH for weak bases (Correct)
